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ABSTRACT 
Objective: To obtain formulations of Celastrol (Cst) nanoemulgel via transdermal route. Celastrol is classified in BCS 4 class as an anti-inflammatory 
drug. These routes are considered to reduce the risk of Celastrol side effects and have the same characteristics as skin morphology. 
Methods: Celastrol nanoemulgel was prepared by a high-pressure homogenizer (HPH) technique. To find the optimum nanoemulsion area by using 
the Chemix 7.00 ternary phase program. Celastrol nanoemulgel was evaluated by measuring the particle size, PDI, morphology, zeta potential, 
stability tests and in vitro using Franz diffusion cell 
Results: Results showed the ideal formula based on the ternary phase diagram using chemix 7.00 is oil: smix: water (5:45:50), with particle size 
89.9±5 nm, PDI 0.1, and zeta-21 mV. The morphological shape is quite spherical ≤ 100±5 nm. The pH value of this formula is 4.5, which compatible 
with the pH of the skin. The highest recovery rate of Celastrol and encapsulation efficiency (EE) were formulas 3 μg/ml and 5 μg/ml, with EE 
91.70% and 94.54%, respectively. In vitro test results showed that the formula 3 μg/ml and 5 μg/ml give better penetration results than the formula 
2.5 μg/ml. Thus, Celastrol nanoemulgel formula has good potential to be developed as a transdermal anti-inflammatory drug. 
Conclusion: Transdermal nanoemulgel containing Celastrol has been successfully developed with particle size ≤ 200±2 nm. 
Keywords: Celastrol (Cst), Transdermal nanoemulgel, Anti-inflammatory, Franz diffusion cells (SDF) 
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INTRODUCTION  
Celastrol (Cst) is a nutritious compound derived from Tripterygium 
wilfordii Hook F (TWFH) isolates. It can be used to treat several 
immune system disorders and neuroprotective, as an anti-
inflammatory for various causes of inflammation, especially 
autoimmune disorders [1]. 
Celastrol is part of the pentacyclic Triterpenoid natural compound 
from the methyl quinone family. This class of compounds has anti-
inflammatory and anti-pain activity. Many studies about Celastrol’s 
pharmacological activity as an anti-inflammatory, found that the 
compound works at the target receptors that trigger inflammation 
from various pathways. These include cytokine pathways (TNF-α, IL-
1, IL-6 and IL-8), as well as the formation of cyclooxygenase 1 and 2 
pathways (COX 1 and 2). through inhibiting catalytic activity 
(sPLA2IIA), which produces the eicosanoid formation of arachidonic 
acid (AA)) [2]. Celastrol’s physical and chemical properties make it 
difficult to dissolve in water, which causes problems with the 
developing of Celastrol as a formula. Celastrol has a Log P value of 
5.63, which, in the pharmaceutical system, is categorized as 
Biopharmaceutical Classification System 4 (BCS 4). Pharmaceutical 
drugs, in the BCS 4 category, have very low solubility and 
permeability.  
Therefore, delivering this active substance requires a formula 
development approach, and this study will use the nanoparticle 
system. Theoretically, the smaller the nanoparticle size, the more it 
can increase compound's ability of these compounds to be absorbed 
or the greater the surface area to penetrate a membrane. Changing 
the drug administration route from oral to transdermal means the 
Celastrol compounds can be formulated in line with the development 
of nanotechnology formulas [3]. Formulations can be developed 
from to Celastrol with the nanotechnology approach, which aims to 
improve these compounds' solubility and bioavailability. Among 
them are the phytosome Celastrol, Celastrol liposomes Celastrol 
nanomicel, NLC Celastrol, and the most recent, Niosom Celastrol and 
Dendrimers Celastrol. The method was developed into peroral, IP, 
and topical routes. The study results concluded that Celastrol 
developed into nanotechnology increased the absorption efficiency 
(EE) to 98.06% with an average particle size of 89.6±7.3 nm ≤100 
nm and zeta potential of 87.8±5.8 mV [4-8]. 
There are no published studies on the Celastrol compound’s 
potential if it is developed to be administrated via other routes. For 
example, transdermal routes have similar characteristics to 
nanoemulsion technology. It is known that nanoemulsion, when 
developed into the transdermal route, shows optimal work results 
with promising pharmaceutical dosage forms [9, 10]. 
The transdermal nanoemulgel has properties in common with the 
stratum corneum (sc), which is the main obstacle of the transdermal 
route. The oil base content on the nanoemulgel base will provide its 
own benefits in therapy. 
The Nanoemulgel’s ingredients can adhere to the skin’s surface and 
gradually increase its hydration. They can also can stretch the skin’s 
permeability, which causes changes in polarity, fluidity, and fat 
exchange between cells in the skin, ultimately facilitating active 
substances penetration into systemic tissue. 
When developing a transdermal route, the active ingredient must have 
considered, along with characteristics such as inertness, constant in 
various temperatures, stable in acidic conditions (pH), polarity, 
toxicity, allergenic, molecular weight ˂ around 450 Da, and low 
melting point, Further, it should not irritate the skin. Celastrol meets 
the above conditions so it is worth trying in its development into the 
transdermal route with the nanoemulgel dosage form [11, 12]. 
This study aims to develop a transdermal nanoemulgel Celastrol 
preparation formula by evaluating its anti-inflammatory activity in 
vitro and in vivo. 
MATERIALS AND METHODS 
Chemicals and animals 
The materials used in this study are; Celastrol standard obtained 
from Xi'an Fengzu Biological Technology Co., Ltd., and Celastrol 
samples obtained from Xi'an Huisun Bio-Tech Co., L. td (PRC). 
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Isopropilmiristat (IPM), Polysorbatum 80 (Tween 80), 
Propylenglycolum (PG), API (Aqua Pro Injection), Ethanol 96%, 
Methyl Paraben, Propyl Paraben, and 305 sepigels, from PT. Bratako 
Tbk., (Jakarta). Merck methanol pro analyse, Acetonitrile pro analyse 
merck, formic acid pro analysis, The tools used are; duran and pyrex 
chemical glass tools, including beaker glass 50 ml, 100 ml, 250 ml, 
500 ml, 1500 ml, 2000 ml. 10 ml, 50 ml, 100 ml measuring cups. 7.5 
cm amplifier cup, stirring rod, measuring flask 2 ml, 5 ml, 10 ml, 50 
ml, 100 ml and 250 ml, thermometer, pH meter, Cole Parmer® 
Viscometer, Shimadzu HPLC, Particles size analyzer (PSA) 
Malvern®, Ultra Turrax 20,000 rpm T25 Digital Homogenizer (120 V 
USA), GEA Brazilian high-pressure homogenizser (HPH). 
Determination of standard Celastrol calibration curves 
First, we placed 10 mg of the standard Celastrol in a 10.0 ml 
volumetric flask and added methanol as a solvent to the mark. Then 
dilution was made as many as 6 (six) concentrations, namely 5 ppm, 
10 ppm, 50 ppm, 100 ppm, 250 pp, and 500 ppm. Subsequently, an 
analysis was carried out by HPLC at a wavelength of 230 nm using 
an inverted phase c-18 column with a mobile phase of acetonitrile: 
0.1% solution of formic acid (85:15) v/v. The results were calculated 
to obtain a linear calibration curve [13].  
Optimization of nanoemulsion areas with ternary phase 
diagrams 
The optimizing process used the pseudo ternary triangle method, 
which aims to obtain a stable nanoemulsion area. This process 
involved mixing surfactant and co-surfactant materials from various 
concentrations that were suitable for the active substance’s physical-
chemical properties. The nanoemulsion optimization was carried 
out by a high energy method involving stirring using an ultraturrax 
20,000 rpm for 15 min. The nanoemulsion area was arranged using 
Chemix 7.00 software. Previous research used the Chemix 7.00 
program to find good, stable nanoemulsion areas in the pseudo 
ternary triangle to facilitate further work [14]. 
Nanoemulsion was developed using Isopropylmiristate (IPM) as oil 
phase, tween 80 as the surfactant, and propylene glycol as co-
surfactant, while distilling water as the water phase. The formulas 
were compared based on the area of nanoemulsion formed as a 
result of the Chemix 7.00 program. For example, a mixture of 
surfactants and co-surfactants called smixes (9: 1 to 1: 9) will show 
stable results. All nanoemulsion formula results were carried out by 
the desired particle size analysis in the research objective of 100 nm 
for the transdermal route using a particle size analyzer (PSA) 
Malvern® [15]. 
Using pseudoterner models in the manufacture of nanoemulsion 
formulations was considered the best way to determine the 
composition of the three constituent elements in nanoemulsion 
preparations  
If the particle size were still bigger than 500 nm, we used a HPH 
machine with a setting of 600 bars and 8 cycles [16].  
Selection of selected formulas from the nanoemulsion area 
After obtaining the nanoemulsion area from the Chemix 7.00 
program, we selected the best, most stable formula and entered the 
active Celastrol substance into the nanoemulsion. 
Celastrol inserted into the nanoemulsion formula, was divided into 3 
(three) forms of Celastrol doses of 2.5 μg/ml, 3 μg/ml and 5 μg/ml 
respectively. 
Manufacture of Celastrol nanoemulgel 
We obtained 2 grams of sepigel® 305 gel added 20 ml of CO2-free 
distilled water and then put it into 100 ml of nanoemulsion 
preparations for each Celastrol dose while stirring using ultra 
turrax® 20,000 rpm for 15 min until homogeneous [17].  
The F1 control, F2 control and F3 control were made with a base of 
gel sepigel® 305. Each Celastrol dose (2.5 μg/ml, 3 μg/ml and 5 
μg/ml) was added to a container containing 100 added gel bases 
0.1% DMSO is stirred using ultra turrax® for 15 min with 20,000 
RPM [18]. 
Evaluation of Celastrol nanoemulgel preparations 
Organoleptic, pH, and homogeneity testing 
Organoleptic testing of Celastrol nanoemulgel preparations carried 
out by direct observation of the preparations physical apperances, 
starting from the physical form of nanoemulgel, and the 
characteristic odor of Celastrol compounds [19].  
pH measurement 
One gram of Celastrol nanoemulgel preparations was obtained from 
each formula, put into a 100 ml glass beaker, dissolved with 100 ml 
distilled water, and stirred using a stirring rod. We measured the pH 
value using a pH measuring device brand Eutech Instrument pH meter 
510 (Singapore). Ideally, the pH that penetrates the skin via the 
transdermal route is 4.5-6.5. Each Celastrol nanoemulgel preparation 
that had been formed was tested for homogeneity by weighing 1 gram 
of the preparation and then sprinkling it on a transparent glass plate. 
Visual observation was carried out under bright light [20]. 
Particle size, polarity index (PDI), zeta potential 
The test is carried out using each Celastrol nanoemulgel that has 
been formed in a 1 mg weigh carefully and then dissolved with 
distilled water up to 9 ml. The solution was taken as much as 100 µl 
and put into a PSA cuvette container and then analyzed using a 
Marvern® particle size analyzer at 25 °C [21].  
Cycling test 
Dispersion stability testing is carried out in 6 (six) cycles. Each cycle 
starts from 4±2 °C for 24 h; the preparation is then transferred to 
another storage area at 40±2 °C for the next 24 h [22].  
Viscosity 
Viscosity was measured using a Cole Parmer® viscometer [23, 24].  
Morphology of the preparation 
The morphological examination of the preparations was carried out 
using a JOEL (JEM-1010) JOEL Brand Transmission Electron 
Microscopy. The procedure was carried out by taking 0.2 µl of a 
Celastrol nanoemulgel preparation using uranyl acetate dye 2% 
(w/v) 0.2 µl, which was dripped on the cooper grid plate. 
Furthermore, observations were made at a magnifications of 30,000, 
50,000 and 100,000 times [25, 26].  
Test the physical stability of the preparation 
The Celastrol nanoemulgel preparations were tested under three 
different temperatures for 12 w, including odor, color, and pH. Each 
preparation was stored at a cold temperature at 4±2 °C, then at room 
temperature at 28±2 0 C, and lastly at a hot temperature at 40±2 °C [27].  
Franz penetration test cell diffusion (SDF) 
The penetration test phase of Celastrol nanoemulgel preparation 
was carried out in vitro at a pH of 7.4 using a phosphate buffer 
solution. The procedure added 0.2 M potassium dihydrogen 
phosphate to 39.1 ml of 0.2 N sodium hydroxide supplemented with 
CO2-free distilled water to a pH of 7.4 [28].  
The the skin test was conducted on male rats, aged 8 w, with a 
bodyweight of±200-250 g, The rats were anesthetized using 0.1% 
ketamine by inhalation. The rat's skin was cleaned with a hair 
shaver, and the skin was sliced by removing the fat part slowly. The 
obtained skin was soaked into a phosphate buffer solution of pH 7.4 
for 30 min at 4 C, which can only be used within the first 24 h [29].  
From the Franz diffusion cells tool calibration results, a surface area 
of 1,766 cm2 and an average compartment volume of 16.0 ml were 
obtained. The rat skin position was placed in the donor 
compartment. Then a 1.0-gram sample preparation is carefully 
placed over the skin, which contained a phosphate buffer solution at 
a pH of 7.4 at the receptor site. A sampling of 1.0 ml was carried out 
at 8 points with a certain time interval of 2, 4, 6, 8, 10, 12, 20, 24 h at 
37 0 C from the receptor compartment. The most important thing in 
using SDF is to keep the sink well maintained by entering the same 
amount in the receptor compartment, that is 1.0 ml [30].  
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First, 1.0 ml of the sample was taken from the receptor compartment 
channel and put into a 5.0 ml flask, which was sufficient with the 
methanol pro analyzed solvent (p. a) to the mark limit on the flask. 
Then 20.0 µl was taken and analyzed by HPLC at a wavelength of 
230 nm using a mobile phase of acetonitrile: 0.1% formic acid 
solution (85:15) flow rate of 1.0 ml. The area from the HPLC analysis 
results is entered into the calibration curve equation, and the 
Celastrol content is calculated in the receptor compartment. All 
HPLC analyses were performed 3 (three) times [31].  
Assay of the Celastrol 
For each dose of 2.5 µg/ml, 3 µg/ml, and 5 µg/ml, 1 gram of Celastrol 
nanoemulgel preparation as added to a solvent of 5 ml methanol 
pro-analysis (pa) in a centrifuge tube, then centrifuged thoroughly at 
4500 rpm for 30 min. The supernatant formed in a 100.0 µl pipette 
and analyzed by HPLC at a wavelength of 230 nm using a mobile 
phase of acetonitrile: 0.1% formic acid solution (85:15) flow rate of 
1.0 ml. The area of HPLC analysis results obtained was calculated 
Celastrol levels based on the calibration curve equation [32].  
Determination of Celastrol levels in nanoemulgel preparations 
For each dose of the Celastrol nanoemulgel preparation, 500 mg was 
added to a centrifuge tube with a methanol pro-analysis (p. a) 
solvent to 5 ml. The solution was centrifuged 4500 rpm for 30 min. 
The precipitate obtained was separated from the supernatant, and 
then the precipitate was dissolved with methanol up to 5 ml filtered 
using a 0.22 µm syringe filter. The obtained filtrate was analyzed by 
HPLC at a wavelength of 230 nm using a mobile phase of 
acetonitrile: 0.1% formic acid solution (85:15) flow rate of 1.0 ml. 
The results of HPLC analysis obtained in calculating Celastrol levels 
are based on the calibration curve equation [33].  
Determination of cumulative levels 
All hourly measurements of Celastrol levels obtained in the in vitro 
Franz diffusion cells (SDF) test, were graphed between the 
cumulative amounts of Celastrol penetrated per unit time of 
sampling. So that the cumulative levels of Celastrol, which will 
penetrate the surface area of the skin membrane of rats, the 
following equation was used [34].  
 
Information:  
Q = cumulative number of Celastrol per unit surface area membrane 
(µg/cm2) 
Cn = Celastrol concentration (µg/cm2) for each extract Sample 
V = Franz diffusion cell volume (µl) 
Vs = sample volume (µl) n-1 
∑ = total Celastrol concentration (µg/ml) 
t = 1 for each sample from 1 to n-1 
S = sample volume, 1.0 ml 
A = Surface area of the membrane, which is 1.7666 cm2 
Flux is obtained from a graph with steady state conditions 
based on Fick’s Law 
 
Information:  
J = Flux under steady state ((µg cm2 h-1) 
S = Area of diffusion area (cm-2) 
M = Amount 
Determination of Celastrol nanoemulgel type 
Each nanoemulgel type, initially weighed±250 mg nanoemulgel 
Celastrol preparation, was placed on the object-glass, then dripped 
Sudan III for the oil phase and methylene blue for the water phase. 
The object-glass was again placed on the first plate that contained 
the preparation, and pressed precisely, for improved accuracy. Then 
the samples on these plates were observed on an Olympus ® 
electron microscope (maximum enlargement). Microscope 
examination results showed that the nanoemulgel preparations 
developed were nanoemulsion type M/A or O/W. 
RESULTS AND DISCUSSION 
The Celastrol calibration curve is linear with a correlation coefficient 
(r2 = 0.9992) in the concentration range from 5 to 500 μg/ml as 
shown in fig. 1. 
 
 
Fig. 1: Calibration curve of celastrol 
 
The results of the evaluation of preparations of Celastrol 
nanoemulgel preparations were obtained each dose. the physical 
form of nanoemulgel is opaque white color following the FG-NCP 
transparent color indicator 
The pH measurements obtained with different pH values tended to 
fall by 2 points from the first day of testing before the 12-day cycle 
stability test every 24 h. The first time the Celastrol nanoemulgel has 
just been prepared for direct pH testing using a pH measuring device 
brand Eutech Instrument pH meter 510 (Singapore). The first pH 
was 7.19 24 h, the pH value dropped by 2 points to 4.79 and during 
the next 24 h of the cycle, the pH values were 4.77, 4.79, 4.90, 4.95 
and 4.93. The pH value of Celastrol can cause a decrease to around 
4.6 [35].  
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Organoleptic homogeneity testing shows that all dosage of Celastrol 
nanoemulgel are evenly shaped, with no visible layers or forms of 
damage from nanoemulgel preparations, such as coalescence, 
sedimentation, flocculation, cremation, or breaking. 
  
 
Fig. 2: Example availability. a. Celastrol Nanoemulsion. b. Nanoemulgel Celastrol c. Base gel form of sepigel 305® 
 
Optimization results of the ternary ratio 1: 9 to 9: 1 phase of oil, smix 
(tween80+PG) and water from a ratio of 90% water to 50% water 
obtained by nanoemulsion bases according to a ternary ratio of 
5:45:50 and oil phase IPM: smix (tween80+PG): water. 
 
















Celastrol 2.5 3 5 2.5 3 5 
IPM 5 5 5 5 5 5 
Smix  45 45 45 45 45 45 
Aquadest 50 50 50 50 50 50 
Metil Paraben 0.05 0.05 0.05 0.05 0.05 0.05 
Propil paraben 0.05 0.05 0.05 0.05 0.05 0.05 
Sepigel® 305 2 2 2 2 2 2 
CO2 Free water 20 20 20 20 20 20 
IPM: Isopropyl Myristate, Smix: Tween 80 and propylene glycol 
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4 
√ x x √ 9 2
1 




√ √ x √ 15 3
5 
√ √ x x 
4 6 x x x √ 8 1
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√ √ x √ 20 3
0 
x x x x 












√ x x √ 25 2
5 
√ x x √ 
6 4 x √ x √ 1
2 








√ √ x √ 30 2
0 
√ x x x 
7 3 x x x √ 1
4 
6 √ x x √ 2
1 




√ √ x √ 35 1
5 
x x x √ 
8 2 x x x √ 1
6 
4 √ x x √ 2
4 
6 x √ x √ 3
2 
8 √ x x √ 40 1
0 
√ x x √ 
9 1 x x x √ 1
8 
2 √ √ x √ 2
7 
3 x √ x √ 3
6 
4 √ x x √ 45 5 x √ x √ 
Explanation: 1 = Globul Size (nm)<500, 2 = Polydispersitas (PDI)<0,3, 3 = Diamater Globul 90 (D90) (nm)<200 nm, 4 = Zeta Potensial, (mV)>±20-35. 
 
Tests with PSA (Particle Size Analyzer) on selected 
nanoemulsions obtained from particle size intensity analysis, 
showed an average particle size of 187.7 nm. However, when 
viewed from the analytical results of D90 intensity, a particle 
size of 343 nm was obtained, meaning that from the overall 
formula of nanoemulsion preparation, 90% of the particles are 
343 nm. Only 10% have particle sizes below 200 nm. Overall, 
this cannot be accepted as the chosen base formula because it 
does not follow the desired transdermal route condition, which 
is below ≤ 200 nm. The PDI and zeta values obtained were 
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sufficient to meet the requirements of a fairly good formula, that 
is, 0.2 and-20.1 mV. In theory, 0.2 in the polydispersity index is a 
heterogeneity index in a sample medium of a mixture of 
polymers and colloids or can be said to be the level of uniformity 
of particle size distribution, while the value of 0.2-0.3 is 
interpreted as a population distribution of homogeneous sizes 
which can be accepted as a mixture of polymer-based and 
colloidal nanoparticle preparations. When compared with other 
research that does not display particle size based on the 
developed formula [36]. 
Then the particle size reduction step was carried out by the high 
energy method, using a HPH at a capacity of 300 bar and carried 
out for 10 cycles for all Celastrol nanoemulgel formulas 2.5 
µg/ml, 3 µg/ml and 5 µg/ml. Then the particle size was 
measured again using a PSA (particle size analyzer) to obtain the 
particle size (z-average, D10, D50, and D90), polydispersity 
index (PDI), and zeta potential. The results obtained from these 
tests obtained a particle size for the intensity distribution that 
was under this study’s objectives, and the desired transdermal 
route was 200 nm (table 3). 
 
Table 3: Results of PSA before and after HPH 
Preparations formula Evaluation 
Globul size (Nanometers) Polydispersity index (PDI) Zeta potential (mV) D 90 (Nanometers) 
Nanoemulsion base non 
celastrol 
187.7 0.2 -20.1 343 
Nanoemulsion Celastrol before homogenized with HPH 
F1 231.03 0.5 -38 672 
F2 272.9 0.5 -35.9 698 
F3 325.9 0.5 -27.6 496.3 
Nanoemulsion Celastrol After homogenized with HPH 
F1 91.5 0.1 -15 158.6 
F2 99.9 0.1 -24.2 182.3 
F3 70.4 0.1 -15.3 119.3 
 
The above results show that the nanoemulgel preparation method 
involving high energy had very good results and produced very 
small particle sizes. This phenomenon occurs due to the pressure 
generated by the HPH. The cycle process was repeated according to 
the desired particle size. From the experiment of Gotu kola extract 
nanoemulsion, researchers obtained an average particle size of 
198.4 nm with PDI 0.329 and zeta-30.9 mV after using HPH with 600 
bar at 8 cycles to reduce the particle sizes of nanoemulsion [37]. 
Akbas, Soyler and Oztop, 2018 studied capsicin nanoemulsion in 
chilies, had an average particle size of 65 nm using HPH method with 
140 bars in 5 cycles. Other experiments formulated an olive oil 
nanoemulsion had an average particle size of 275 nm with a 
pressure of 450 bar in 4 cycles using HPH. High-pressure 
homogenizer method is very effective for reducing the particle sizes 
of colloidal dispersions [38, 39].  
For the evaluation results of the Celastrol nanoemulgel preparations 
organoleptic test, from all doses obtained, pH and homogeneity 
showed the resulting preparations, in the form of opaque colored 
nanoemulgel, matched the drug dosage color index, namely FG NCP 
Transparant White, pH value 7.19, when the preparation was 
complete. However, the pH decreased after a cycle endurance test for 
12 d in a row. The results can be seen in (fig. 3). The pH reduction in 
these preparations is due to the Celastrol compound’s physical and 
chemical properties, which basically have a pH between 4–6. 
  
 
Fig. 3: Graph of the pH test cycle 
 
The Celastrol nanoemulgel preparations were spread evenly on the 
transparent clear glass surface for all doses of formula made. The 
measurement results of the viscosity of nanoemulsion and Celastrol 
nanoemulgel preparations indicated that, at all dosages, the 
nanoemulsion viscosity values were 20 cP and 21 cP for 
nanoemulgel. This shows that the viscosity level of the two is not 
significantly different because the value is only 1 point difference, 
which can be interpreted that the preparation can flow well without 
flow resistance from the material composition of each preparation 
compiler. The flow rate (rheology) of nanoemulsion preparations 
seems to follow Newton's law by using spindle 1, shows a linear 
straight line. However, in theory, based on dispersion both 
suspension and colloid drug preparations tend to have a relationship 
with Newton's law (fig. 2). Based on testing the flow properties of 
celestrol nanoemulgel, using spindle no. 4 (four), the curved 
graphical shape is generated both up and down (fig. 4). 
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Fig. 4: Viscosity graph of celastrol nanoemulgel 
 
The explanation in the test is that the nanoemulgel Celastrol 
preparation has flow properties that follow the non-Newton law of 
pseudoplastic type; it is caused by an increase in the shear rate of a 
liquid and semi-solid preparation, so the viscosity decreased. The 
constituent components of Celastrol nanoemulgel may cause this 
event because they come from the long-chain group of tween 80, and 
the medium-chain triglyceride of oil. The pseudoplastic type of 
Celastrol nanoemulgel indicated that the preparation cannot be 
poured when it is in a storage container. This is shown in the graphic 
image, which shown that the up and down lines coincide so that each 
viscosity value is always different since the pseudoplastic type does 
not have an absolute viscosity value [40]. 
  
 
Fig. 5: The results of the ternary area nanoemulsion triangle optimization using the chemix 7.00 program 
 
The effect of pH on a pharmaceutical preparation’s viscosity value is 
significant, as seen in testing the Celastrol nanoemulgel preparation for 
formulas 1, 2, and 3. The same viscosity value is 20 cP. However, the pH 
test on day 0 obtained, respectively pH value 7.19 for F1, 7.15 for F2, and 
7.09 for F3. On the 28th day, the pH value changed quite significantly. 
The event was also caused by the gel-based material, namely sepigel 
305®, which basically consists of an emulsion-based component with an 
intermediate chain group that form chain bonds that extend into the flow 
by increasing inflow shear velocity to the next shear pressure. This 
affects each preparation formula’s viscosity (fig. 3 and 4). 
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Fig. 6: Franz diffusion cells test results graph, F1: NEG 25 µg/ml, F2: NEG 3 µg/ml, F3: NEG 5 µg/ml (NEG Cst: Nanoemulgel), F1: EG 2.5 
µg/ml, F2: EG 3 µg/ml, F3: EG 5 µg/ml (+DMSO 0.1%) (EG: Emulgel Cst), cumulative of total Celastrol penetrated. All values were 
represented as mean±SD (n=3) 
 
 
Fig. 7: Average penetration flux of nanoemulgel celastrol (Cst) and emulgel Cst+0.1% DMSO (mean±SD, n=3), F1: NEG 2,5 µg/ml, F2: NEG 3 
µg/ml, F3: NEG 5 µg/ml (NEG Cst: nanoemulgel), F1: EG 2.5 µg/ml, F2: EG 3 µg/ml, F3: EG 5 µg/ml (+DMSO 0.1%) (EG: emulgel cst) 
 
The results of the determination of Celastrol in the assay test in the 
nanoemulgel preparations obtained levels of 90.98% for F1, 91.70%, 
and 74.50%. For example, in formulation 1 with a dose of 2.5 µg/ml if 
100 ml of v/v preparation were made into 100.2 grams of the dosage 
after adding a 305® sepigel basis, the percentage of the 2.5 µg/ml dose 
that what mixed was calculated in the whole preparation. By weighing 
a sample of 1.0 gram carefully and analyzing it by HPLC, the 
percentage of the area on the HPLC was calculated. 
To determine the level of Celastrol in nanoemulgel preparations, i.e., 
how much Celastrol was absorbed, the adsorption efficiency (EE) of 
the remaining sediment was calculated after centrifuging at 4500 
rpm for 30 min. The results, in F1 were 79.46%, F2 85.54% and F3 
94.54%. 
In vitro penetration tests, using Franz diffusion cells (CDF) (fig. 6.7), 
show that the formula 2.5 μg/ml Celastrol nanoemulgel has difficulty 
to penetrate the mouse skin membrane, compared to the 
concentrated formula 3 μg/ml and 5 μg/ml. Those formulas (3 
μg/ml and 5 μg/ml) penetrated very well through the mouse skin 
membrane. This can be caused by the small cumulative amount of 
Celastrol content in the donor compartment in formula 1 (2.5 
μg/ml), affecting the level of penetration or flux. In addition, the 
three nanoemulgel formulas considered to have better penetration 
capabilities than the control formula, which is not a nano formula, 
even the control formula is added by 0.1% DMSO to facilitate 
penetration. The results obtained that the nanoemulgel formula was 
still superior to the control formula. 
 
 
Fig. 8: TEM Morphology result a. before and b. after HPH 
Isah et al. 
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Fig. 10: Particles size analyser (PSA) 
 
CONCLUSION 
Transdermal nanoemulgel containing Celastrol has been developed 
successfully to obtain a nanoemulsion area that is suitable for the 
purpose of the transdermal route of ≤ 200±2 nm. 
By using Celastrol as an active ingredient, 5% isopropyl myristate 
(IPM) as the oil phase, tween 80, and propyleneglycol (PG) are both 
referred to as smix 45% and 50% water, in comparison (5:45:50). 
The combination of these preparations resulted in the size of the 
particle size of globules for the average D90 in each preparation 
formula made was 2.5 μg/ml 176±2 nm, 3 μg/ml 189±2 nm, and 5 
μg/ml 121±2 nm. The potential zeta values obtained were-14.6 mV,-
24.8 mV,-4.86 mV, and the PDI value for all formulas was 0.1. In vitro 
test results of all transdermal nanoemulgel Celastrol preparations 
produced better penetration than control preparations containing 
Celastrol+0.1% DMSO gel. 
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